Achieve Life Sciences Inc. priced a $12 million underwritten public offering.
The offering comprises class A units, priced $4 per unit, and class B units, priced $1,000 apiece.
Each class A unit consists of 1 common share and a five-year warrant to buy 1 common share. Each class B unit comprises one share of series A preferred stock — convertible into 250 shares — and a five-year warrant to buy 250 common shares. The warrants have an exercise price of $4 per share. The securities that make up the units will be issued separately.
The pharmaceutical company said it is offering a total of 710,500 common shares, 9,158 shares of series A preferred stock, convertible into 2,289,500 common shares, and total warrants to buy 3 million common shares.
The underwriters have an option to buy up to 450,000 common shares or warrants to buy up to 450,000 common shares.
The offering is expected to close on or about June 19.
Ladenburg Thalmann Financial Services Inc. unit Ladenburg Thalmann & Co. Inc. is the sole book-running manager for the offering.
Bothell, Wash.-based Achieve Life Sciences develops and sells therapies that address treatment resistance in cancer patients.